The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.
 
David Camidge
Honoraria - Abbvie; Apollomics; AstraZeneca; Daiichi Sankyo; Janssen; Kestrel Labs; Lilly; Nuvalent, Inc.; Roche; takeda
Research Funding - Inivata (Inst)
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Shirish Gadgeel
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avistone Biotechnology (Inst); Bayer (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GRAIL (Inst); Helsinn Therapeutics (Inst); Incyte (Inst); InventisBio (Inst); Iovance Biotherapeutics (Inst); Jacobio (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Kymera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Nimbus Therapeutics (Inst); Novita Pharmaceuticals (Inst); Numab (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Tango Therapeutics (Inst); Turning Point Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Merck; Mirati Therapeutics
Other Relationship - AstraZeneca
 
Kristof Cuppens
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ITeos Therapeutics; Janssen; MSD; Pierre Fabre; Roche/Genentech
Expert Testimony - AstraZeneca; MSD
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Janssen; MSD; Roche/Genentech
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Daiichi Sankyo; Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Hidehito Horinouchi
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; BlossomHill Therapeutics, Inc.; Chugai Pharma; Daiichi Sankyo; Genmab; Novocure; Seagen; Yuhan
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BlossomHill Therapeutics, Inc. (Inst); BMKK (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Chong Kun Dang Pharmaceutical; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Merck KGaA; Novartis; Regeneron; Roche; Samsung Bioepis; Takeda
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Enliven Therapeutics (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Yuhan (Inst)
 
Angelo Delmonte
No Relationships to Disclose
 
Elvire Pons-Tostivint
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Janssen; Roche; Sanofi Pasteur; Takeda
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Pfizer; Roche/Genentech; Roche/Genentech; Sanofi; Takeda
 
Robert Jotte
Leadership - Sarah Cannon Research Institute
Consulting or Advisory Role - AstraZeneca
 
Nivedita Aanur
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Han Coburn
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Qi Jiang
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Theodore Jennaro
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Tony Navas
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Yan Li
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Jonathan Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst)